Bioxytran (OTCMKTS:BIXT) Posts Quarterly Earnings Results

Bioxytran (OTCMKTS:BIXT) released its earnings results on Friday. The company reported ($0.02) EPS for the quarter, Zacks reports.

Bioxytran Stock Performance

OTCMKTS:BIXT traded down $0.00 during mid-day trading on Friday, hitting $0.03. 4,000 shares of the company’s stock traded hands, compared to its average volume of 83,667. The company has a market cap of $3.74 million, a PE ratio of -1.65 and a beta of 1.95. Bioxytran has a 1 year low of $0.03 and a 1 year high of $0.17. The firm’s 50 day simple moving average is $0.04 and its 200 day simple moving average is $0.05.

About Bioxytran

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.